CY1116377T1 - Αναστολεις της ανθρωπινης πρωτεϊνικης φωσφατασης της τυροσινης και μεθοδοι χρησης - Google Patents
Αναστολεις της ανθρωπινης πρωτεϊνικης φωσφατασης της τυροσινης και μεθοδοι χρησηςInfo
- Publication number
- CY1116377T1 CY1116377T1 CY20151100409T CY151100409T CY1116377T1 CY 1116377 T1 CY1116377 T1 CY 1116377T1 CY 20151100409 T CY20151100409 T CY 20151100409T CY 151100409 T CY151100409 T CY 151100409T CY 1116377 T1 CY1116377 T1 CY 1116377T1
- Authority
- CY
- Cyprus
- Prior art keywords
- methods
- suspensions
- tyrosine protein
- human tyrosine
- protein phosphate
- Prior art date
Links
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 title abstract 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 title abstract 3
- 229910019142 PO4 Inorganic materials 0.000 title 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 title 1
- 239000010452 phosphate Substances 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 239000000725 suspension Substances 0.000 title 1
- 230000006269 (delayed) early viral mRNA transcription Effects 0.000 abstract 2
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 abstract 2
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 abstract 2
- 230000033115 angiogenesis Effects 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- 230000001105 regulatory effect Effects 0.000 abstract 2
- 102000003839 Human Proteins Human genes 0.000 abstract 1
- 108090000144 Human Proteins Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/28—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- AIDS & HIV (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US81673106P | 2006-06-27 | 2006-06-27 | |
| US81682506P | 2006-06-27 | 2006-06-27 | |
| US81673006P | 2006-06-27 | 2006-06-27 | |
| EP07809908.2A EP2038265B1 (en) | 2006-06-27 | 2007-06-27 | Human protein-tyrosine phosphatase inhibitors and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1116377T1 true CY1116377T1 (el) | 2017-02-08 |
Family
ID=38704715
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20151100409T CY1116377T1 (el) | 2006-06-27 | 2015-05-08 | Αναστολεις της ανθρωπινης πρωτεϊνικης φωσφατασης της τυροσινης και μεθοδοι χρησης |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US7795444B2 (https=) |
| EP (3) | EP2038265B1 (https=) |
| JP (6) | JP5261383B2 (https=) |
| KR (1) | KR101179087B1 (https=) |
| AU (1) | AU2007265454B2 (https=) |
| BR (1) | BRPI0713357A2 (https=) |
| CA (1) | CA2657107C (https=) |
| CO (1) | CO6150140A2 (https=) |
| CY (1) | CY1116377T1 (https=) |
| DK (1) | DK2038265T3 (https=) |
| ES (1) | ES2534392T3 (https=) |
| HU (1) | HUE024976T2 (https=) |
| IL (1) | IL196129A (https=) |
| MX (1) | MX2009000289A (https=) |
| NZ (1) | NZ574406A (https=) |
| PL (1) | PL2038265T3 (https=) |
| PT (1) | PT2038265E (https=) |
| SI (1) | SI2038265T1 (https=) |
| WO (1) | WO2008002570A2 (https=) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7226755B1 (en) * | 2002-09-25 | 2007-06-05 | The Procter & Gamble Company | HPTPbeta as a target in treatment of angiogenesis mediated disorders |
| US7507568B2 (en) * | 2002-09-25 | 2009-03-24 | The Proctor & Gamble Company | Three dimensional coordinates of HPTPbeta |
| RU2494108C2 (ru) | 2006-04-07 | 2013-09-27 | Аерпио Терапетикс, Инк. | Антитела, которые связывают человеческий белок бета-тирозин фосфатазу (нртрвета), и их использование |
| US7795444B2 (en) | 2006-06-27 | 2010-09-14 | Warner Chilcott Company | Human protein tyrosine phosphatase inhibitors and methods of use |
| US20130023542A1 (en) * | 2006-06-27 | 2013-01-24 | Aerpio Therapeutics Inc. | Human protein tyrosine phosphatase inhibitors and methods of use |
| US7589212B2 (en) * | 2006-06-27 | 2009-09-15 | Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
| US7622593B2 (en) | 2006-06-27 | 2009-11-24 | The Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
| US8846685B2 (en) | 2006-06-27 | 2014-09-30 | Aerpio Therapeutics Inc. | Human protein tyrosine phosphatase inhibitors and methods of use |
| US9096555B2 (en) | 2009-01-12 | 2015-08-04 | Aerpio Therapeutics, Inc. | Methods for treating vascular leak syndrome |
| DK2385763T3 (en) * | 2009-01-12 | 2018-07-16 | Aerpio Therapeutics Inc | METHODS OF TREATING VASCULAR LEAK SYNDROME |
| AU2014202211B2 (en) * | 2009-01-12 | 2016-06-02 | EyePoint Pharmaceuticals, Inc. | Methods for treating vascular leak syndrome |
| AU2016203254B2 (en) * | 2009-01-12 | 2018-09-13 | EyePoint Pharmaceuticals, Inc. | Methods for treating vascular leak syndrome |
| US8883832B2 (en) | 2009-07-06 | 2014-11-11 | Aerpio Therapeutics Inc. | Compounds, compositions, and methods for preventing metastasis of cancer cells |
| ES2726946T3 (es) | 2009-07-06 | 2019-10-10 | Aerpio Therapeutics Inc | Derivados de benzosulfonamida, composiciones de los mismos y su uso en la prevención de la metástasis de las células cancerosas |
| RS54010B1 (sr) | 2009-11-06 | 2015-10-30 | Aerpio Therapeutics Inc. | Inhibitori prolil hidroksilaze |
| NZ610230A (en) * | 2010-10-07 | 2015-07-31 | Aerpio Therapeutics Inc | Compositions and methods for treating ocular edema, neovascularization and related diseases |
| BR112014008759A8 (pt) | 2011-10-13 | 2017-09-12 | Aerpio Therapeutics Inc | Tratamento de doença ocular |
| WO2013056240A1 (en) | 2011-10-13 | 2013-04-18 | Aerpio Therapeutics, Inc. | Methods for treating vascular leak syndrome and cancer |
| US9962362B2 (en) * | 2012-03-29 | 2018-05-08 | Children's Hospital Medical Center | Use of small molecule inhibitors targeting EYA tyrosine phosphatase |
| US9220710B2 (en) * | 2013-01-09 | 2015-12-29 | Gilead Sciences, Inc. | Therapeutic compounds |
| WO2014113407A2 (en) | 2013-01-16 | 2014-07-24 | Children's Hospital Medical Center | Use of small molecule inhibitors targeting eya tyrosine phosphatase |
| US20150050277A1 (en) | 2013-03-15 | 2015-02-19 | Aerpio Therapeutics Inc. | Compositions and methods for treating ocular diseases |
| AU2014233363B2 (en) * | 2013-03-15 | 2017-06-29 | EyePoint, Inc. | Compositions, formulations and methods for treating ocular diseases |
| US9388135B2 (en) | 2014-02-19 | 2016-07-12 | Aerpio Therapeutics, Inc. | Process for preparing N-benzyl-3-hydroxy-4-substituted-pyridin-2-(1H)-ones |
| EP3116503A4 (en) | 2014-03-14 | 2017-08-23 | Aerpio Therapeutics, Inc. | Hptp-beta inhibitors |
| WO2016022813A1 (en) | 2014-08-07 | 2016-02-11 | Aerpio Therapeutics, Inc. | Combination of immunotherapies with activators of tie-2 |
| JP6746614B2 (ja) * | 2015-05-27 | 2020-08-26 | 杏林製薬株式会社 | ウレア誘導体、またはその薬理学的に許容される塩 |
| ES2894802T3 (es) | 2015-09-23 | 2022-02-15 | Aerpio Pharmaceuticals Inc | Activadores de Tie-2 para su uso en el tratamiento de la presión intraocular |
| JP6690282B2 (ja) | 2016-02-15 | 2020-04-28 | 住友電気工業株式会社 | 炭化珪素エピタキシャル基板および炭化珪素半導体装置の製造方法 |
| BR112019001206A2 (pt) | 2016-07-20 | 2019-06-25 | Aerpio Therapeutics Inc | anticorpos monoclonais humanizados que visam ve-ptp (hptp-ss) |
| JP6801472B2 (ja) * | 2017-01-25 | 2020-12-16 | スズキ株式会社 | 船外機の表示装置 |
| WO2020068653A1 (en) | 2018-09-24 | 2020-04-02 | Aerpio Pharmaceuticals, Inc. | MULTISPECIFIC ANTIBODIES THAT TARGET HPTP - β (VE-PTP) AND VEGF |
| EP3962482A4 (en) | 2019-04-29 | 2023-01-11 | EyePoint Pharmaceuticals, Inc. | TIE 2 ACTIVATORS FACING THE SCHLEMM CHANNEL |
| US11413242B2 (en) | 2019-06-24 | 2022-08-16 | EyePoint Pharmaceuticals, Inc. | Formulations of Tie-2 activators and methods of use thereof |
| WO2021086904A1 (en) | 2019-10-29 | 2021-05-06 | Aerpio Pharmaceuticals, Inc. | Small molecule activators of tie-2 |
| CN117460743A (zh) * | 2020-06-16 | 2024-01-26 | 曼宁研究公司 | 小分子ve-ptp抑制剂 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4673641A (en) | 1982-12-16 | 1987-06-16 | Molecular Genetics Research And Development Limited Partnership | Co-aggregate purification of proteins |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE69332197T2 (de) | 1992-03-13 | 2003-04-17 | Organon Teknika B.V., Boxtel | Epstein-Barr-Virus verwandte Peptide und Nukleinsäuresegmenten |
| US5770565A (en) | 1994-04-13 | 1998-06-23 | La Jolla Cancer Research Center | Peptides for reducing or inhibiting bone resorption |
| US5688781A (en) | 1994-08-19 | 1997-11-18 | Bristol-Myers Squibb Company | Method for treating vascular leak syndrome |
| IL160406A0 (en) | 1995-06-15 | 2004-07-25 | Crucell Holland Bv | A cell harbouring nucleic acid encoding adenoritus e1a and e1b gene products |
| AR022303A1 (es) * | 1999-01-22 | 2002-09-04 | Lundbeck & Co As H | Derivados de piperidina, tetrahidropiridina y piperazina, su preparacion y utilizacion |
| EP1046715A1 (en) | 1999-04-23 | 2000-10-25 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Interaction of vascular-endothelial protein-tyrosine phosphatase with the angiopoietin receptor tie-2 |
| WO2000065088A2 (en) | 1999-04-26 | 2000-11-02 | Amersham Pharmacia Biotech Ab | Primers for identifying typing or classifying nucleic acids |
| US6342219B1 (en) | 1999-04-28 | 2002-01-29 | Board Of Regents, The University Of Texas System | Antibody compositions for selectively inhibiting VEGF |
| AU5147700A (en) | 1999-05-19 | 2000-12-05 | Amgen, Inc. | Crystal of a lymphocyte kinase-ligand complex and methods of use |
| WO2001016097A1 (en) | 1999-08-27 | 2001-03-08 | Sugen, Inc. | Phosphate mimics and methods of treatment using phosphatase inhibitors |
| US6589758B1 (en) | 2000-05-19 | 2003-07-08 | Amgen Inc. | Crystal of a kinase-ligand complex and methods of use |
| EP1409540A2 (en) | 2000-09-27 | 2004-04-21 | The Procter & Gamble Company | Melanocortin receptor ligands |
| AU2003222127A1 (en) * | 2002-03-29 | 2003-10-13 | Ontogen Corporation | Sulfamic acids as inhibitors of human cytoplasmic protein tyrosine phosphatases |
| US7507568B2 (en) | 2002-09-25 | 2009-03-24 | The Proctor & Gamble Company | Three dimensional coordinates of HPTPbeta |
| US7226755B1 (en) | 2002-09-25 | 2007-06-05 | The Procter & Gamble Company | HPTPbeta as a target in treatment of angiogenesis mediated disorders |
| US20050154011A1 (en) * | 2003-02-20 | 2005-07-14 | The Procter & Gamble Company | Tetrahydroisoquinolnyl sulfamic acids |
| US7588924B2 (en) | 2006-03-07 | 2009-09-15 | Procter & Gamble Company | Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase |
| RU2494108C2 (ru) | 2006-04-07 | 2013-09-27 | Аерпио Терапетикс, Инк. | Антитела, которые связывают человеческий белок бета-тирозин фосфатазу (нртрвета), и их использование |
| US7589212B2 (en) | 2006-06-27 | 2009-09-15 | Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
| US7795444B2 (en) | 2006-06-27 | 2010-09-14 | Warner Chilcott Company | Human protein tyrosine phosphatase inhibitors and methods of use |
| US7622593B2 (en) | 2006-06-27 | 2009-11-24 | The Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
| US7769557B2 (en) * | 2008-07-01 | 2010-08-03 | Honeywell International Inc. | Multi-gas flow sensor with gas specific calibration capability |
| DK2385763T3 (en) | 2009-01-12 | 2018-07-16 | Aerpio Therapeutics Inc | METHODS OF TREATING VASCULAR LEAK SYNDROME |
| ES2726946T3 (es) | 2009-07-06 | 2019-10-10 | Aerpio Therapeutics Inc | Derivados de benzosulfonamida, composiciones de los mismos y su uso en la prevención de la metástasis de las células cancerosas |
-
2007
- 2007-06-26 US US11/821,846 patent/US7795444B2/en active Active
- 2007-06-27 PT PT78099082T patent/PT2038265E/pt unknown
- 2007-06-27 SI SI200731650T patent/SI2038265T1/sl unknown
- 2007-06-27 NZ NZ574406A patent/NZ574406A/en not_active IP Right Cessation
- 2007-06-27 KR KR1020097001694A patent/KR101179087B1/ko not_active Expired - Fee Related
- 2007-06-27 AU AU2007265454A patent/AU2007265454B2/en not_active Ceased
- 2007-06-27 MX MX2009000289A patent/MX2009000289A/es active IP Right Grant
- 2007-06-27 EP EP07809908.2A patent/EP2038265B1/en not_active Not-in-force
- 2007-06-27 EP EP17187910.9A patent/EP3293182A1/en not_active Withdrawn
- 2007-06-27 EP EP12196179.1A patent/EP2592073B1/en not_active Not-in-force
- 2007-06-27 DK DK07809908.2T patent/DK2038265T3/en active
- 2007-06-27 ES ES07809908.2T patent/ES2534392T3/es active Active
- 2007-06-27 HU HUE07809908A patent/HUE024976T2/en unknown
- 2007-06-27 PL PL07809908T patent/PL2038265T3/pl unknown
- 2007-06-27 JP JP2009518227A patent/JP5261383B2/ja not_active Expired - Fee Related
- 2007-06-27 CA CA2657107A patent/CA2657107C/en active Active
- 2007-06-27 WO PCT/US2007/014823 patent/WO2008002570A2/en not_active Ceased
- 2007-06-27 BR BRPI0713357-0A patent/BRPI0713357A2/pt not_active Application Discontinuation
-
2008
- 2008-12-23 IL IL196129A patent/IL196129A/en active IP Right Grant
-
2009
- 2009-01-27 CO CO09007334A patent/CO6150140A2/es unknown
-
2010
- 2010-08-04 US US12/850,026 patent/US8106078B2/en not_active Expired - Fee Related
-
2011
- 2011-12-01 US US13/309,445 patent/US8329916B2/en not_active Expired - Fee Related
-
2013
- 2013-02-19 JP JP2013029649A patent/JP2013091669A/ja not_active Withdrawn
-
2015
- 2015-05-08 CY CY20151100409T patent/CY1116377T1/el unknown
- 2015-09-10 JP JP2015178320A patent/JP2016026176A/ja not_active Withdrawn
- 2015-09-10 JP JP2015178321A patent/JP2015221837A/ja active Pending
-
2017
- 2017-11-06 JP JP2017213854A patent/JP2018048190A/ja not_active Withdrawn
- 2017-11-06 JP JP2017213855A patent/JP2018016657A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1116377T1 (el) | Αναστολεις της ανθρωπινης πρωτεϊνικης φωσφατασης της τυροσινης και μεθοδοι χρησης | |
| CY1115588T1 (el) | Αναστολεις ανθρωπινης πρωτεϊνικης φωσφατασης τυροσινης-β και η φαρμακευτικη χρηση τους | |
| CY1123625T1 (el) | Συνθεσεις και μεθοδοι για θεραπεια διαταραχων χρησης αλκοολης, πονου και αλλων ασθενειων | |
| WO2008002569A3 (en) | Human protein tyrosine phosphatase inhibitors and methods of use | |
| EA200900828A1 (ru) | Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1 | |
| ATE548374T1 (de) | 2'-fluor-2'-desoxytetrahydrouridine als cytidindeaminaseinhibitoren | |
| UA101478C2 (ru) | Соединения, полезные как ингибиторы raf-киназы | |
| EA200901313A1 (ru) | Ингибиторы тирозинкиназы брутона | |
| NO20081636L (no) | FAP - inhibitorer | |
| BR112012008624A2 (pt) | inibidores de tirosina quinase de bruton | |
| ATE530540T1 (de) | Pyrimidonverbindungen als gsk-3-inhibitoren | |
| CY1114872T1 (el) | Συνθεσεις και μεθοδοι χρησης αντισωματων εναντι της σκληροστεϊνης | |
| EA200802213A1 (ru) | Способы лечения заболеваний крови | |
| ECSP099027A (es) | Anticuerpos anti-dll4 y métodos que los usan | |
| EA201000149A1 (ru) | Производные 1-фенил-2-пиридинилалкиловых спиртов в качестве ингибиторов фосфодиэстераз | |
| EA201070247A1 (ru) | Ингибиторы протеасом | |
| EA200801291A1 (ru) | Карбониламинопирролопиразолы в качестве эффективных ингибиторов киназ | |
| EA200970156A1 (ru) | Пиридизиноновые производные | |
| EA200870391A1 (ru) | Тетрагидропирролопиримидиндионы и их применение в качестве ингибиторов эластазы нейтрофилов человека | |
| MEP52808A (en) | Aminoheteroaryl compounds as protein kinase inhibitors | |
| NO20082026L (no) | Deazapuriner som er nyttige som inhibitorer for Janus-kinaser | |
| HRP20070043A2 (hr) | Antivirusna sredstva | |
| NO20083501L (no) | Azaindoler som er anvendelige som inhibitorer for Janus-kinaser | |
| EA200971051A1 (ru) | Ингибиторы p70 s6 киназы | |
| EA201170590A1 (ru) | Ингибиторы рецептора фактора роста фибробластов-3 (fgfr-3) и способы лечения |